BI
REGN icon

Bramshill Investments’s Regeneron Pharmaceuticals REGN Stock Holding History

Bramshill Investments’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-27
Closed -$10K – 167
2018
Q4 		$10K Hold
27
– – ﹤0.01% 156
2018
Q3 		$11K Buy
+27
New +$10.3K ﹤0.01% 172

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bramshill Investments's REGN Position: Q1 2019 in Review

Bramshill Investments sold out of Regeneron Pharmaceuticals (REGN) in Q1 2019, closing a stake of 27 shares — an estimated $10K sold.

Bramshill Investments first reported a position in REGN in Q3 2018 and held it in 2 quarters. The position peaked at $11K in Q3 2018. 718 funds tracked by Wall St. Rank hold REGN as of Q1 2019.

  • Bramshill Investments reported no remaining Regeneron Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Bramshill Investments sold 27 Regeneron Pharmaceuticals shares in Q1 2019, an estimated $10K.
  • Bramshill Investments first reported a position in Regeneron Pharmaceuticals in Q3 2018 and held it in 2 quarters.
  • Bramshill Investments's Regeneron Pharmaceuticals position peaked at $11K in Q3 2018.
  • 718 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2019.

Based on Bramshill Investments's 13F filing for Q1 2019, filed 15 May 2019.